CADILA

PHARMACEUTICAL
GROUP – C
 INTRODUCTION
o r • A private pharmaceutical Company
f
ila ” • 50 therapeutic areas over 50 countries
ad ty
“C ali
• Started by Mr. Modi and Mr. Patel
•
Q u • Rs. 25,000 Rs. 8,000 crore
• Health care as national need
 Planning

• Long Term Planning via Short Term Planning

• Budgeting : based on Return over Investment

• Launching of new product : gets exclusivity
• Failure of product
a.) Strategies were wrong
b.) Entered wrong market
• Government Policies
• Marketing Strategies :
2000 M.R.
Rural Network “Explora”
 Planning contd…
 5 critical Forces of Planning
1. Distribution channel, Financial Resources
2. Supplier Power
3. Buyer Power
4. Competition
5. Product substitute

 PEST Analysis
 Future projects and Swine flu
 Exclusive from company
 Organization Structure
Head of the
Department Special Departments :
Vice-President
• R & D (Foundation for
growth)
Deputy General • Marketing
Manager

Executives

Assistants

Workers
 Controlling

• Over Quality

Quality Control and Analytical Research lab

Quality Assurance & Quality Control Dept.

• Over Production

• Over Time limit of Production

• Monthly Board Meetings

• Employee considered as a part of

company family
• “Modi Benevolent Fund”
 Analysis

• BCG matrix
 SWOT Analysis
Strength Weakness Opportunities Threat
Research Generally brand Future products The extensive
capabilities and specific (HAA) having bio use of chemical
production, but, as such no molecules as molecule which
organization weakness major component may not survive
structure, highly in future
experienced
management.
Widespread We think that lack Swine flu vaccine N.A.
distribution of promotion
network through media
may be a
weakness.
Company’s N.A. Fruitful ties with N.A.
constant growth Gujarat
government